【摘要】 目的:探讨重组组织型纤溶酶原激活剂(rt-PA)静脉溶栓治疗房颤及非房颤急性缺血性卒中患者的疗效及安全性。方法:纳入rt-PA静脉溶栓治疗发病4.5 h内急性缺血性卒中患者61例,分为房颤组22例和非房颤组39例。比较2组的基线特征,采用NIHSS及mRS量表评定溶栓前及溶栓后2 h、24 h、7 d、90 d的疗效。结果:房颤组男性人数、起病至开始溶栓时间均低于非房颤组,首次收缩压高于非房颤组,差异均有统计学意义(均P<0.05)。2组溶栓后2 h、24 h、7 d NIHSS评分、7 d疗效、90 d mRS评分差异无统计学意义(P>0.05)。结论:rt-PA治疗房颤急性缺血性卒中患者疗效及安全性与非房颤患者相当。更多还原

【Abstract】 Objective: To investigate the safety and efficacy of thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator(rt-PA) in acute ischemic stroke of patients with or without atrial fibrillation(AF). Methods: Consecutive acute ischemic stroke patients(n=61) treated with intravenous rt-PA within 4.5 h after stroke onset were studied. The patients were divided into groups AF(n=22) and Non-AF(n=39). The clinical characteristics of the two groups were compared. NIHSS and mRS were used to assess the efficacy and safety before thrombolysis and 2 h, 24 h, 7 d, 90 d respectively after thrombolysis. Results: The percentage of males and the median time for the administration of rt-PA were lower in the AF group then those in the Non-AF group(P<0.05). The prime SBP was higher in the AF group than that in the Non-AF group. There were no significant differences in the NIHSS at 2 h, 24 h, and 7 d, the efficacy at 7 d, and the mRS at 90 d after thrombolysis between the two groups. Conclusion: There were no significant differences in the safety and efficacy of thrombolytic therapy with rt-PA in treating acute ischemic stroke of patients with or without AF.更多还原